Note 4 - Acquisition of Grace (Details Textual) - USD ($) $ in Thousands		12 Months Ended
	Aug. 27, 2021	Mar. 31, 2022	Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]
Net loss attributable in the consolidated statement of income (loss)		$ (9,819)	$ (19,678)
Goodwill		12,964
Grace Therapeutics Inc Member
Restructuring Cost and Reserve [Line Items]
Total common shares issued (in shares)	18,241,233
Business Combination, Acquisition Related Costs		3,200
Net loss attributable in the consolidated statement of income (loss)		1,505
Finite-lived Intangible Assets Acquired	$ 69,810
Increase in finite-lived Intangible Assets		4,602
Goodwill	12,964	12,964
Deferred tax liability	17,536	17,536
Adjustments to net assets		$ 30
Grace Therapeutics Inc Member | In Process Research And Development Member
Restructuring Cost and Reserve [Line Items]
Finite-lived Intangible Assets Acquired	$ 69,810